Hutchison Medipharma Limited clinical trials

A subsidiary of HUTCHMED

The registry lists 68 studies whose lead sponsor is Hutchison Medipharma Limited. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 27, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 68. List all 68 → · All HUTCHMED studies →

• A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingNCT05015621Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsCompletedNCT05173142Phase 1/2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsCompletedNCT04923932Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)CompletedNCT03223376Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerCompletedNCT05509699Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerCompletedNCT04322539Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT04923945Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersCompletedNCT03251378Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia PatientsCompletedNCT03951623Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedNCT02857998Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care ExistedCompletedNCT03128164Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different ManufacturersCompletedNCT05318820Early Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine TumorsCompletedNCT02589821Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine TumorsCompletedNCT02588170Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid TumorsCompletedNCT04169672Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Surufatinib Renal Impairment StudyCompletedNCT04755088Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Surufatinib Hepatic Impairment StudyCompletedNCT04755075Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCTStatus unknownNCT05277454Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerStatus unknownNCT02897479Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Fruquintinib Food Effect and Proton Pump Inhibitor StudyCompletedNCT04645940Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Surufatinib DDI With a PPI and a CYP3A InducerCompletedNCT04510649Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Fruquintinib CYP3A Inhibitor and Inducer StudyCompletedNCT04557397Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy SubjectsCompletedNCT04372394Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy SubjectsCompletedNCT04372407Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Study of HMPL-523 in Relapsed or Refractory Hematologic MalignanciesStatus unknownNCT02503033Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Phase II Study of HMPL-004 in Patients With Ulcerative ColitisCompletedNCT00659802Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02133157Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/NeoplasmsStatus unknownNCT04272957Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• HMPL-813 in Treating Patients With GlioblastomaStatus unknownNCT03231501Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• HMPL-453 in Advanced Malignant MesotheliomaStatus unknownNCT04290325Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Study of Fruquintinib in Patients With Metastatic Colorectal CancerCompletedNCT02196688Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)CompletedNCT02320409Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCCompletedNCT02374645Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy SubjectsCompletedNCT01955304Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)CompletedNCT02314819Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric CancerCompletedNCT02415023Phase 1/2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid TumorsCompletedNCT02590952Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid TumorsCompletedNCT01645215Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase Ib Study of Fruquintinib in 3rd Line mCRCCompletedNCT01975077Phase 1/2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02590965Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid TumorCompletedNCT02601248Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid CarcinomaCompletedNCT02614495Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] FruquintinibCompletedNCT02689752Phase 1

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma PatientsStatus unknownNCT03873532Phase 2/3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Study of HMPL-453 in Patients With Advanced Solid MalignanciesStatus unknownNCT03160833Phase 1/2

  Sponsor listed in the registry: Hutchison Medipharma Limited

• HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative ColitisTerminatedNCT01882764Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative ColitisTerminatedNCT01805791Phase 3

  Sponsor listed in the registry: Hutchison Medipharma Limited

• Phase II Study of HMPL-004 in Subjects With Crohn's DiseaseCompletedNCT00655733Phase 2

  Sponsor listed in the registry: Hutchison Medipharma Limited